Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739826 | 0.89 | ACHE (0.54) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL548539 | 0.86 | ACHE (0.53) | ACHEKIF11ALDH1A1CES2MEN1 | |
| SCHEMBL21132592 | 0.84 | ACHE (0.56) | ACHEKIF11ALDH1A1CES2MEN1 | |
| SCHEMBL6559598 | 0.84 | KIF11 (0.51) | ACHEKIF11ALDH1A1CES2MEN1 | |
| SCHEMBL179538 | 0.83 | RXRA (0.66) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL7771557 | 0.83 | ACHE (0.65) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL2173132 | 0.83 | ACHE (0.65) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL16957957 | 0.83 | ACHE (0.58) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL19987946 | 0.82 | RXRA (0.64) | ACHERXRARXRBHDAC8HDAC6 | |
| SCHEMBL1360237 | 0.82 | ACHE (0.62) | ACHERXRARXRBHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| EP-4470537-A1 | COMPOUND FOR USE IN TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) | Queen's University At Kingston (CA) | 2024-12-04 | — | — | EP | disclosed |
| EP-4470536-A1 | COMPOUND FOR USE IN TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) | Queen's University At Kingston (CA) | 2024-12-04 | — | — | EP | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | ACHE 751/4885RXRA 2422/4885RXRB 2935/4885 |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | SQSTM1, HSPA5, ATG7 | ACHE 4678/4885RXRA 2887/4885RXRB 2738/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ACHE 414/4885RXRA 4803/4885RXRB 4806/4885 |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | ACHE 1173/4885RXRA 2658/4885RXRB 2627/4885 |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | LMTK3, LMTK2, LIMK1 | ACHE 4573/4885RXRA 4521/4885RXRB 4144/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | ACHE 814/4885RXRA 494/4885RXRB 350/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | ACHE 965/4885RXRA 4342/4885RXRB 4122/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ACHE 414/4885RXRA 4803/4885RXRB 4806/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | ACHE 3695/4885RXRA 503/4885RXRB 244/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | ACHE 4793/4885RXRA 215/4885RXRB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.